Business

Altimmune has announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a contract worth up to $120.2 million over five years for clinical development of NasoShield intranasal anthrax vaccine.… Read more . . .

US-based Cannabis Science has announced that it “will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers.” According to the company, the product would be available “in states where marijuana is… Read more . . .

Vectura has filed a patent infringement suit against GlaxoSmithKline after GSK said that it would not exercise its option for additional patent licenses for various Ellipta DPI products under a 2010 agreement. Many of the… Read more . . .

Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide therapies for cystic fibrosis and other indications, has filed a request to withdraw its registration statement for an initial public offering. The company announced its… Read more . . .

Smartinhaler maker Adherium has announced an upcoming $8 million AUD ($6 million USD) share placement to Fidelity International, increasing Fidelity’s holdings in the company to 10%. The shares will be issued on July 26, 2016.… Read more . . .

Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential… Read more . . .

Therapix Biosciences has entered into an agreement with the Hebrew University’s technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university’s Institute… Read more . . .

AeroVanc developer Savara Pharmaceuticals has acquired Serendex Pharmaceuticals, which is developing Molgradex inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). Serendex announced in September 2015 that it was initiating… Read more . . .

In May 2016, Grupo Ferrer announced that it would acquire inhaled drug company Alexza Pharmaceuticals; as of June 21, 2016, the company says, Ferrer Pharma has merged into Alexza Pharmaceuticals, with Alexza now a wholly… Read more . . .

US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex’s generic budesonide inhalation suspension, a generic version of AstraZeneca’s Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture,… Read more . . .